Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management team will present and participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 4:30 pm Pacific Time.
At the conference, Lyell executives will highlight the company’s growing pipeline of product candidates targeting solid tumors and T-cell reprogramming technologies, including its:
- Lead CAR T cell and TIL product candidates, LYL797 and LYL845, which are in Phase 1 clinical development;
- Second-generation ROR1 targeting CAR T-cell product candidate, LYL119, that incorporates two new reprogramming technologies
- Newest stackable genetic and epigenetic reprogramming technologies:
- NR4A3 gene knockout, that is being incorporated along with c-Jun overexpression to enhance the functional activity of CAR T cells; and
- Stim-RTM, a programmable cell-signaling platform that optimizes signaling parameters during T-cell activation in order to generate more potent CAR T cells
A live webcast of the presentation can be accessed through the Investors section of the Company’s website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days following the presentation date.
About Lyell Immunopharma, Inc.
Lyell is a clinical-stage T-cell reprogramming company advancing a pipeline of therapies designed to address what it believes are the primary barriers that limit consistent and long-lasting responses to adoptive T-cell therapy: T cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop new medicines with improved and durable clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington. To learn more, please visit www.lyell.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell’s anticipated progress, business plans, business strategy, planned research and clinical trials and plans to present at the conference; the growing pipeline of product candidates and T-cell reprogramming technologies and the potential clinical benefits and therapeutic potential of such product candidates and technologies; the potential of Lyell’s reprogramming technologies to overcome primary barriers to successful adoptive cell therapy in solid tumors, including the ability for Lyell’s new genetic and epigenetic reprogramming technologies to enhance the functional activity of CAR T cells and to generate more potent CAR T cells, and Lyell’s plans for such reprogramming technologies; and other statements that are not historical fact. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the effects of the COVID-19 pandemic; geopolitical instability; macroeconomic conditions; Lyell’s ability to submit planned INDs or initiate or progress clinical trials on the anticipated timelines, if at all; Lyell’s lack of experience as a company in enrolling, conducting or completing clinical trials; Lyell’s ability to manufacture and supply its product candidates for its clinical trials; the preclinical profiles of Lyell’s product candidates not translating in clinical trials; the potential for results from clinical trials to differ from preclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell’s product candidates; the significant uncertainty associated with Lyell’s product candidates ever receiving any regulatory approvals; Lyell’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell’s strategic plans for its business and product candidates; the sufficiency of Lyell’s capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading “Risk Factors” in Lyell’s most recently filed quarterly report on Form 10-Q and subsequent filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Senior Vice President, Communications and Investor Relations